Encapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency

Biomaterials

Volumn 35, Issue 35, 2014, Pages 9554-9561

  Mendez, Natalie ^a   Herrera, Vanessa ^a   Zhang, Lingzhi ^c   Hedjran, Farah ^c   Feuer, Ralph ^b   Blair, Sarah L ^a   Trogler, William C ^a   Reid, Tony R ^a   Kummel, Andrew C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN DIEGO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Adenovirus; Drug delivery; Gene therapy; Liposome; Nanoparticle; Phospholipid

Indexed keywords

DISEASES; DRUG DELIVERY; DRUG THERAPY; GENE THERAPY; IMMUNE SYSTEM; LECITHIN; LIPOSOMES; NANOPARTICLES; PHOSPHOLIPIDS; SELF ASSEMBLY; VIRUSES;

ADENOVIRUS; CANCER THERAPEUTICS; GENETIC PATHWAYS; IMMUNE RESPONSE; IMMUNOPRECIPITATIONS; METASTATIC TUMORS; ONCOLYTIC VIRUS; TRANSFECTION EFFICIENCY;

COMPUTER VIRUSES;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ADENOVIRUS VECTOR; CHOLESTEROL; FOLATE RECEPTOR; FOLIC ACID; LIPOSOME; MACROGOL 2000; NEUTRALIZING ANTIBODY; PHENFORMIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL; PHOSPHOLIPID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CONTROLLED STUDY; DISPERSION; GENETIC TRANSFECTION; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; HYDRODYNAMICS; IMMUNOPRECIPITATION; LIPOSOMAL GENE DELIVERY SYSTEM; MICROENCAPSULATION; MOLECULAR STABILITY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; VIRUS INFECTIVITY; VIRUS PLAQUE; ZETA POTENTIAL; 129 MOUSE; ADENOVIRIDAE; ANIMAL; CHEMISTRY; CLASSIFICATION; GENE THERAPY; HEK293 CELL LINE; ISOLATION AND PURIFICATION; ONCOLYTIC VIROTHERAPY; PROCEDURES; TUMOR CELL LINE;

ADENOVIRIDAE; MIRIDAE;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; GENETIC THERAPY; HEK293 CELLS; HUMANS; IMMUNOPRECIPITATION; LECITHINS; LIPOSOMES; MICE; MICE, 129 STRAIN; ONCOLYTIC VIROTHERAPY; TRANSFECTION;

EID: 84926042523     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.08.010     Document Type: Article

References (55)

1. Breitbach C.J., Reid T., Burke J., Bell J.C., Kirn D.H. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev 2010, 21(2-3):85-89.
2. Heise C.C., Williams A.M., Xue S., Propst M., Kirn D.H. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res 1999, 59(11):2623-2628.
3. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?. Gene Ther 2001, 8(2):89-98.
4. Yamamoto M., Curiel D.T. Current issues and future directions of oncolytic adenoviruses. Mol Ther 2010, 18(2):243-250.
5. Hecht J.R., Bedford R., Abbruzzese J.L., Lahoti S., Reid T.R., Soetikno R.M., et al. Aphase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003, 9(2):555-561.
6. DeWeese T.L., van der Poel H., Li S., Mikhak B., Drew R., Goemann M., et al. Aphase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001, 61(20):7464-7472.
7. Liu T.-C., Galanis E., Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Prac Oncol 2007, 4(2):101-117.
8. Nemunaitis J., Khuri F., Ganly I., Arseneau J., Posner M., Vokes E., et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. JClin Oncol 2001, 19(2):289-298.
9. Reid T., Galanis E., Abbruzzese J., Sze D., Wein L.M., Andrews J., et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002, 62(21):6070-6079.
10. Khuri F.R., Nemunaitis J., Ganly I., Arseneau J., Tannock I.F., Romel L., et al. Acontrolled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000, 6(8):879-885.
11. Alemany R., Balagué C., Curiel D. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000, 18(7):723.
12. Yamamoto M., Curiel D.T. Cancer gene therapy. Technol Cancer Res Treat 2005, 4(4):315-330.
13. Yamamoto M. Conditionally replicative adenovirus for gastrointestinal cancers. Expert Opin Biol Ther 2004, 4(8):1241-1250.
14. Yamamoto M., Curiel D.T. Nonreplicating DNA viral vectors for suicide gene therapy: the adenoviral vectors. Methods Mol Med 2004, 90:61-70.
15. Mulvihlll S., Warren R., Venook A., Adler A., Randlev B., Heise C., et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 2001, 8(4):308-315.
16. Ganly I., Kirn D., Eckhardt S.G., Rodriguez G.I., Soutar D.S., Otto R., et al. Aphase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000, 6(5):798-806.
17. Lamont J.P., Nemunaitis J., Kuhn J.A., Landers S.A., McCarty T.M. Aprospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 2000, 7(8):588-592.
18. Nemunaitis J., Cunningham C., Buchanan A., Blackburn A., Edelman G., Maples P., et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001, 8(10):746-759.
19. Makower D., Rozenblit A., Kaufman H., Edelman M., Lane M.E., Zwiebel J., et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res 2003, 9(2):693-702.
20. Hamid O., Varterasian M.L., Wadler S., Hecht J.R., Benson A., Galanis E., et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. JClin Oncol 2003, 21(8):1498-1504.
21. Nemunaitis J., Cunningham C., Tong A.W., Post L., Netto G., Paulson A.S., et al. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther 2003, 10(5):341-352.
22. Portella G., Pacelli R., Libertini S., Cella L., Vecchio G., Salvatore M., et al. ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. JClin Endocrinol Metab 2003, 88(10):5027-5032.
23. Rudin C.M., Cohen E.E.W., Papadimitrakopoulou V.A., Silverman S., Recant W., El-Naggar A.K., et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. JClin Oncol 2003, 21(24):4546-4552.
24. Chiocca E.A., Abbed K.M., Tatter S., Louis D.N., Hochberg F.H., Barker F., et al. Aphase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004, 10(5):958-966.
25. Galanis E., Okuno S.H., Nascimento A.G., Lewis B.D., Lee R.A., Oliveira A.M., et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 2005, 12(5):437-445.
26. Reid T.R., Freeman S., Post L., McCormick F., Sze D.Y. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther 2005, 12(8):673-681.
27. Nemunaitis J., Senzer N., Sarmiento S., Zhang Y.A., Arzaga R., Sands B., et al. Aphase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients. Cancer Gene Ther 2007, 14(11):885-893.
28. Hedjran F., Shantanu K., Tony R. Deletion analysis of Ad5 E1a transcriptional control region: impact on tumor-selective expression of E1a and E1b. Cancer Gene Ther 2011, 18(10):717-723. Epub 2011/08/06.
29. Choi K.J., Kim J.H., Lee Y.S., Kim J., Suh B.S., Kim H., et al. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther 2006, 13(13):1010-1020.
30. Bristol J.A., Zhu M., Ji H., Mina M., Xie Y., Clarke L., et al. Invitro and invivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol Ther 2003, 7(6):755-764.
31. Fagerberg J. Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy. Med Oncol 1996, 13(3):155-160.
32. Yotnda P., Chen D.-H., Chiu W., Piedra P.A., Davis A., Templeton N.S., et al. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther 2002, 5(3):233-241.
33. Ishida T., Harashima H., Kiwada H. Liposome clearance. Biosci Rep 2002, 22(2):197-224.
34. Zhong Z., Han J., Wan Y., Zhang Z., Sun X. Anionic liposomes enhance and prolong adenovirus-mediated gene expression in airway epithelia invitro and invivo. Mol Pharmacol 2011, 8(3):673-682.
35. Zhong Z., Shi S., Han J., Zhang Z., Sun X. Anionic liposomes increase the efficiency of adenovirus-mediated gene transfer to coxsackie-adenovirus receptor deficient cells. Mol Pharmacol 2009, 7(1):105-115.
36. Zhong Z., Wan Y., Han J., Shi S., Zhang Z., Sun X. Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes. Int J Nanomed 2011, 6:1083.
37. Choi J.-W., Lee J.-S., Kim S.W., Yun C.-O. Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev 2012, 64(8):720-729.
38. Gaffen S.L., Liu K.D. Overview of interleukin-2 function, production and clinical applications. Cytokine 2004, 28(3):109-123.
39. Lotze M.T., Zitvogel L., Campbell R., Robbins P.D., Elder E., Haluszczak C., et al. Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials. Ann N Y Acad Sci 1996, 795(1):440-454.
40. Tao N., Gao G.-P., Parr M., Johnston J., Baradet T., Wilson J.M., et al. Sequestration of adenoviral vector by kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001, 3(1):28-35.
41. Waddington S.N., McVey J.H., Bhella D., Parker A.L., Barker K., Atoda H., et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008, 132(3):397-409.
42. Sumida S.M., Truitt D.M., Lemckert A.A., Vogels R., Custers J.H., Addo M.M., et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. JImmunol 2005, 174(11):7179-7185.
43. Roberts D.M., Nanda A., Havenga M.J.E., Abbink P., Lynch D.M., Ewald B.A., et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006, 441(7090):239-243.
44. Corjon S., Wortmann A., Engler T., van Rooijen N., Kochanek S., Kreppel F. Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere. Mol Ther 2008, 16(11):1813-1824.
45. Prill J.-M., Espenlaub S., Samen U., Engler T., Schmidt E., Vetrini F., et al. Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from kupffer cells. Mol Ther 2011, 19(1):83-92.
46. Campos S.K., Barry M.A. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology 2006, 349(2):453-462.
47. Beer S.J., Matthews C.B., Stein C.S., Ross B.D., Hilfinger J.M., Davidson B.L. Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity invivo. Gene Ther 1998, 5(6):740-746.
48. Lee S.G., Yoon S.J., Kim C.D., Kim K., Lim D.S., Yeom Y.I., et al. Enhancement of adenoviral transduction with polycationic liposomes invivo. Cancer Gene Ther 2000, 7(10).
49. Audouy S.L., de Leij L.M.H., Hoekstra D., Molema G. Invivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm Res 2002, 19(11):1599-1605.
50. Filion M.C., Phillips N.C. Major limitations in the use of cationic liposomes for DNA delivery. Int J Pharm 1998, 162(1-2):159-170.
51. Lv H., Zhang S., Wang B., Cui S., Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. JControl Release 2006, 114(1):100-109.
52. Chen X., Park R., Shahinian A.H., Bading J.R., Conti P.S. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 2004, 31(1):11-19.
53. Veronese F.M., Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005, 10(21):1451-1458.
54. Kirby C., Clarke J., Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability invivo and invitro. Biochem J 1980, 186(2):591-598.
55. Allen T.M., Hansen C., Martin F., Redemann C., Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives invivo. Biochim Biophys Acta - Biomembr 1991, 1066(1):29-36.